Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;16(8):1478-86.
doi: 10.1007/s11605-012-1923-5. Epub 2012 Jun 13.

Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma

Affiliations

Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma

Peter Peng et al. J Gastrointest Surg. 2012 Aug.

Abstract

Introduction: Assessing patient-specific risk factors for long-term mortality following resection of pancreatic adenocarcinoma can be difficult. Sarcopenia--the measurement of muscle wasting--may be a more objective and comprehensive patient-specific factor associated with long-term survival.

Methods: Total psoas area (TPA) was measured on preoperative cross-sectional imaging in 557 patients undergoing resection of pancreatic adenocarcinoma between 1996 and 2010. Sarcopenia was defined as the presence of a TPA in the lowest sex-specific quartile. The impact of sarcopenia on 90-day, 1-year, and 3-year mortality was assessed relative to other clinicopathological factors.

Results: Mean patient age was 65.7 years and 53.1 % was male. Mean TPA among men (611 mm²/m²) was greater than among women (454 mm²/m²). Surgery involved pancreaticoduodenectomy (86.0 %) or distal pancreatectomy (14.0 %). Mean tumor size was 3.4 cm; 49.9 % and 88.5 % of patients had vascular and perineural invasion, respectively. Margin status was R0 (59.0 %) and 77.7 % patients had lymph node metastasis. Overall 90-day mortality was 3.1 % and overall 1- and 3-year survival was 67.9 % and 35.7 %, respectively. Sarcopenia was associated with increased risk of 3-year mortality (HR = 1.68; P < 0.001). Tumor-specific factors such as poor differentiation on histology (HR = 1.75), margin status (HR = 1.66), and lymph node metastasis (HR = 2.06) were associated with risk of death at 3-years (all P < 0.001). After controlling for these factors, sarcopenia remained independently associated with an increased risk of death at 3 years (HR = 1.63; P < 0.001).

Conclusions: Sarcopenia was a predictor of survival following pancreatic surgery, with sarcopenic patients having a 63 % increased risk of death at 3 years. Sarcopenia was an objective measure of patient frailty that was strongly associated with long-term outcome independent of tumor-specific factors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
TPA was measured at the level of L3 on the first image with both vertebral spines visible. Measurements were performed in a semi-automated fashion with manual outlining of psoas muscle borders and setting the density threshold between −30 and 110 Hounsfield Units (HU)
Fig. 2
Fig. 2
a When stratified by gender, the mean adjusted TPA was statistically lower for women than for men (454.3 mm2/m2 vs. 611.0 mm2/m2, P<0.001). b Age tended to be associated with the incidence of sarcopenia as there was a trend toward decreasing TPA with increasing age
Fig. 3
Fig. 3
The presence of sarcopenia was also associated with the risk of death (no sarcopenia, 18.0 months; 40.0 % vs. sarcopenia, 13.7 months; 23.0 % median, 3-year survival, respectively; P=0.01)

References

    1. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244(1):10–5. - PMC - PubMed
    1. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–79. - PubMed
    1. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77. - PubMed
    1. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101(6):908–15. - PMC - PubMed
    1. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tact cancer cooperative group. Ann Surg. 1999;230(6):776–82. discussion 82-4. - PMC - PubMed

Publication types

MeSH terms